David Amsellem
Stock Analyst at Piper Sandler
(2.61)
# 2,152
Out of 4,906 analysts
147
Total ratings
61.21%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Reiterates: Overweight | $328 | $295.87 | +10.86% | 4 | Jun 27, 2025 | |
| SAGE Sage Therapeutics | Downgrades: Neutral | $9 → $8.5 | $8.97 | -5.24% | 2 | Jun 17, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $115 | $122.68 | -6.26% | 1 | Jun 12, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $9.45 | +90.48% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $30.91 | +19.70% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $112.65 | +30.49% | 14 | May 7, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 → $154 | $131.83 | +16.82% | 10 | May 6, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $46.69 | +39.22% | 1 | Apr 22, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $128 → $131 | $70.12 | +86.82% | 7 | Apr 3, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $36 → $32 | $21.18 | +51.09% | 8 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $5.14 | -22.18% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $15.60 | -16.67% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $8.90 | +12.36% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.31 | +83.94% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $10.98 | +18.40% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $7.92 | +38.89% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $26.66 | +38.78% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $65.30 | +4.13% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $33.23 | +8.34% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.32 | -52.53% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.18 | +89.36% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $4.23 | +136.41% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $0.76 | +2,650.85% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $109.68 | +3.03% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $35.20 | +19.32% | 3 | Oct 16, 2023 |
Amgen
Jun 27, 2025
Reiterates: Overweight
Price Target: $328
Current: $295.87
Upside: +10.86%
Sage Therapeutics
Jun 17, 2025
Downgrades: Neutral
Price Target: $9 → $8.5
Current: $8.97
Upside: -5.24%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $115
Current: $122.68
Upside: -6.26%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $9.45
Upside: +90.48%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $30.91
Upside: +19.70%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $112.65
Upside: +30.49%
Neurocrine Biosciences
May 6, 2025
Reiterates: Overweight
Price Target: $160 → $154
Current: $131.83
Upside: +16.82%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $46.69
Upside: +39.22%
Corcept Therapeutics
Apr 3, 2025
Maintains: Overweight
Price Target: $128 → $131
Current: $70.12
Upside: +86.82%
Amphastar Pharmaceuticals
Mar 21, 2025
Maintains: Neutral
Price Target: $36 → $32
Current: $21.18
Upside: +51.09%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $5.14
Upside: -22.18%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $15.60
Upside: -16.67%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $8.90
Upside: +12.36%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.31
Upside: +83.94%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $10.98
Upside: +18.40%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $7.92
Upside: +38.89%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $26.66
Upside: +38.78%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $65.30
Upside: +4.13%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $33.23
Upside: +8.34%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.32
Upside: -52.53%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.18
Upside: +89.36%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $4.23
Upside: +136.41%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $0.76
Upside: +2,650.85%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $109.68
Upside: +3.03%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $35.20
Upside: +19.32%